• 1
    Conil JM, Georges B, de Lussy A, Khachman D, Seguin T, Ruiz S, Cougot P, Fourcade O, Houin G, Saivin S. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Antimicrob Agents 2008; 32: 50510.
  • 2
    Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP 1991; 25: 10507.
  • 3
    van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008; 23: 42230.
  • 4
    Zelenitsky SA, Ariano RE. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother 2010; 65: 172532.
  • 5
    Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 107381.
  • 6
    Scaglione F, Esposito S, Leone S, Lucini V, Pannacci M, Ma L, Drusano GL. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J 2009; 34: 394400.
  • 7
    Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995; 15: 27991.
  • 8
    Oudhuis GJ, Verbon A, Hoogkamp-Korstanje JA, Stobberingh EE. Antimicrobial resistance in Escherichia coli and Pseudomonas aeruginosa from Intensive Care Units in The Netherlands, 1998-2005. Int J Antimicrob Agents 2008; 31: 5863.
  • 9
    Nethmap. Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands. 2010.
  • 10
    ECDC. European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe in 2009. 2009.
  • 11
    Perreiter AP, Nix DE, Matthias KR. Appropriateness of ciprofloxacin dosing based on a population pharmacokinetic model. Hosp Pharm 2010; 45: 23743.
  • 12
    Neef C, van Gils SA, IJzerman WL. Analogy between temperature-dependent and concentration-dependent bacterial killing. Comput Biol Med 2002; 32: 52949.
  • 13
    Kontou P, Chatzika K, Pitsiou G, Stanopoulos I, Argyropoulou-Pataka P, Kioumis I. Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. Antimicrob Agents Chemother 2011; 55: 414953.
  • 14
    FDA. Guidance for industry. Bioanalytical method validation. U.S. Department of Health and Food Science, Rockville, MD, USA, Food and Drug Administration (FDA). 2001.
  • 15
    Haeseker MB, Verbon A, Welzen J, Neef C, Bruggeman CA, Stolk LML. A simple and rapid RP-HPLC method to determine ciprofloxacin level In human serum. Asian J Pharm Biol Res 2011; 10092011: 3504.
  • 16
    Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2010; 1: 193209.
  • 17
    Bertino J, Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798817. discussion 797.
  • 18
    Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother 1990; 26: 3144.
  • 19
    Lipman J, Scribante J, Gous AG, Hon H, Tshukutsoane S. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother 1998; 42: 22359.
  • 20
    Alan C, Kocoglu H, Ersay AR, Ertung Y, Kurt HA. Unexpected severe hepatotoxicity of ciprofloxacine: two case reports. Drug Chem Toxicol 2011; 34: 18991.